25 results on '"Angelopoulou, Maria K."'
Search Results
2. Effects of Chemotherapy on Aortic 18-Fluorodeoxyglucose Uptake in Patients With Hodgkin and Non-Hodgkin Lymphoma
- Author
-
Vlachopoulos, Charalambos V., Solomou, Eirini G., Terentes Printzios, Dimitrios G., Pouli, Anastasia G., Sioni, Anastasia, Giannouli, Stavroula E., Angelopoulou, Maria K., Kafouris, Pavlos, Metaxas, Marinos G., Chondropoulos, Spiros D., Stergiou, Ioanna E., Marinakis, Theodoros P., Koutagiar, Iosif, Miliou, Antigoni A., Ioakeimidis, Nikolaos, Tsalamandris, Sotirios T., Katsi, Vasiliki, Aggeli, Constantina I., Voulgarelis, Michael, Tousoulis, Dimitrios M., Tsioufis, Constantinos, and Anagnostopoulos, Constantinos D.
- Published
- 2023
- Full Text
- View/download PDF
3. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
- Author
-
Vassilakopoulos, Theodoros P., Papageorgiou, Sotirios G., Angelopoulou, Maria K., Chatziioannou, Sophia, Prassopoulos, Vassilios, Karakatsanis, Stamatios, Arapaki, Maria, Mellios, Zois, Sachanas, Sotirios, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Kotsopoulou, Maria, Dimou, Maria, Variamis, Eleni, Boutsis, Dimitrios, Terpos, Evangelos, Michali, Evridiki, Karianakis, George, Tsirkinidis, Pantelis, Vadikolia, Chryssa, Poziopoulos, Christos, Pigaditou, Anna, Vrakidou, Effimia, Siakantaris, Marina P., Kyrtsonis, Marie-Christine, Symeonidis, Argyris, Anargyrou, Konstantinos, Papaioannou, Maria, Chatziharissi, Evdoxia, Vervessou, Elissavet, Tsirogianni, Maria, Palassopoulou, Maria, Gainaru, Gabriella, Mainta, Catherine, Tsirigotis, Panagiotis, Assimakopoulou, Theodora, Konstantinidou, Pavlina, Papadaki, Helen, Dimopoulos, Meletios-Athanassios, Pappa, Vassiliki, Karmiris, Themis, Roussou, Paraskevi, Datseris, Ioannis, Panayiotidis, Panayiotis, Konstantopoulos, Kostas, Pangalis, Gerassimos A., and Rondogianni, Phivi
- Published
- 2021
- Full Text
- View/download PDF
4. Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
- Author
-
Vassilakopoulos, Theodoros P., Kravvariti, Evrydiki, Panitsas, Fotios, Angelopoulou, Maria K., Liaskas, Athanasios, Kontopidou, Flora N., Yiakoumis, Xanthoula, Variami, Eleni, Dimopoulou, Maria N., Siakantaris, Marina P., Asimakopoulos, John V., Arapaki, Maria, Dimou, Maria, Diamantopoulos, Panagiotis, Sachanas, Sotirios, Chatzidimitriou, Chrysovalantou, Belia, Marina, Konstantinou, Elianna, Boutsikas, George, Petevi, Kyriaki, Kanellopoulos, Alexandros, Kokoris, Styliani, Kyrtsonis, Marie-Christine, Viniou, Nora-Athina, Lakiotaki, Eleftheria, Tsourouflis, Gerasimos, Korkolopoulou, Penelope, Konstantopoulos, Kostas, Panayiotidis, Panayiotis, and Pangalis, Gerassimos A.
- Published
- 2022
- Full Text
- View/download PDF
5. A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity.
- Author
-
Efstathopoulou, Maria, Zoi, Katerina, Siakantaris, Marina P., Koumbi, Daphne, Zannou, Anna, Triantafyllou, Evangelia-Faidra, Tsourouflis, Gerassimos, Lakiotaki, Eleftheria, Vassilakopoulos, Theodoros P., and Angelopoulou, Maria K.
- Subjects
CHRONIC myeloid leukemia ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,CHRONIC leukemia ,EXTRAMEDULLARY diseases ,T cells - Abstract
Chronic myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC) at diagnosis, without any prior history of CML is extremely rare. After the introduction of tyrosine kinase inhibitors (TKIs), CML patients have a median survival comparable to general population and accelerated/blast crisis are rarely encountered. Most CML patients (80%) transform into acute myeloid leukemia and the rest into B-ALL. Anecdotal cases of Ph+ T-ALL, either de novo or in the context of CML-BC have been reported. Left shift in the blood, the presence of splenomegaly/extramedullary infiltration and the occurrence of BCR::ABL1 rearrangement in both the blastic population, as well as in the myeloid cell compartment are key points in differentiating de novo Ph+ T-ALL from T-ALL CML-BC. The latter is a rare entity, characterized by extramedullary disease, p210 transcript and clonal evolution. Lack of preceding CML does not rule out the diagnosis of T-ALL CML-BC. Prompt TKI treatment with ALL-directed therapy followed by allogeneic stem cell transplantation may offer long-term survival in this otherwise poor prognosis entity. In this paper, we describe a patient with T-ALL CML-BC at presentation, still alive 51 months after diagnosis and we offer a review of the literature on this rare subject. All clinical and laboratory features are provided in order to distinguish de novo Ph+ T-ALL from T-ALL CML-BC, underscoring the prognostic and therapeutic significance of such a differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Prolonged 3-year spontaneous remission of diffuse large B-cell lymphoma upon withdrawal of infliximab and late relapse in a patient with psoriasis: a case report and review of the literature.
- Author
-
Asimakopoulos, John V., Dolkiras, Filippos, Lakiotaki, Eleftheria, Rondogianni, Phivi, Tsourouflis, Gerasimos, Siakantaris, Marina P., Angelopoulou, Maria K., Rondogianni, Dimitra, Korkolopoulou, Penelope, Vlahoyiannopoulos, Panayiotis, and Vassilakopoulos, Theodoros P.
- Subjects
DIFFUSE large B-cell lymphomas ,LITERATURE reviews ,DISEASE relapse ,CUTANEOUS T-cell lymphoma ,INFLIXIMAB ,MUCOSA-associated lymphoid tissue lymphoma - Abstract
Yet, the description of a polymorphic cell infiltration in LN biopsy, the absence of clinical lymphadenopathy at presentation, the history of psoriatic arthritis as well as the preceded treatment with anti-tumor necrosis factor (TNF)- and cyclosporine raised diagnostic concerns. Although the patient could not finally avoid R-CHOP immunochemotherapy, this case highlights that a trial of NBA withdrawal under very close monitoring could be a rational therapeutic choice even in patients with aggressive ID-LPDs. Keywords: diffuse large B-cell lymphoma; psoriasis; infliximab; apremilast; novel biologic agent; anti-TNF EN diffuse large B-cell lymphoma psoriasis infliximab apremilast novel biologic agent anti-TNF 1695 1700 6 10/12/23 20231001 NES 231001 The association of psoriasis with cancer has been a matter of debate, especially in the era of the novel biologic agents (NBA). Lastly, taking into consideration our case with the re-appearance of the lymphoma despite the change of NBA as well as all the other cases described in Table 1, the appearance of LPDs in psoriatic patients is a more complex process influenced by clinical disease duration and extension, the time length of immunosuppression and the nature of the various treatments administered. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
7. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
- Author
-
Vassilakopoulos, Theodoros P., Liaskas, Athanasios, Pereyra, Patricio, Panayiotidis, Panayiotis, Angelopoulou, Maria K., and Gallamini, Andrea
- Subjects
HODGKIN'S disease ,CLINICAL trials ,IMMUNE checkpoint inhibitors ,DISEASE management ,ANTINEOPLASTIC agents ,MONOCLONAL antibodies - Abstract
The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early metabolic response assessed by PET/CT in advanced stage HL, have been the cornerstones of risk stratification and treatment decision-making, minimizing treatment-related complications while keeping efficacy. Nevertheless, a non-negligible number of patients are primary refractory or relapse after front-line treatment. Novel immunotherapeutic agents, namely Brentuximab Vedotin (BV) and immune checkpoint inhibitors (CPI), have already shown outstanding efficacy in a relapsed/refractory setting in recent landmark studies. Several phase 2 single-arm studies suggest that the addition of these agents in the frontline setting could further improve long-term disease control permitting one to reduce the exposure to cytotoxic drugs. However, a longer follow-up is needed. At the time of this writing, the only randomized phase 3 trial so far published is the ECHELON-1, which compares 1 to 1 BV-AVD (Bleomycin is replaced by BV) with standard ABVD in untreated advanced-stage III and IV HL. The ECHELON-1 trial has proven that BV-AVD is safe and more effective both in terms of long-term disease control and overall survival. Just recently, the results of the S1826 SWOG trial demonstrated that the combination nivolumab-AVD (N-AVD) is better than BV-AVD, while preliminary results of other randomized ongoing phase 3 trials incorporating anti-PD-1 in this setting will be soon available. The aim of this review is to present the recent data regarding these novel agents in first-line treatment of HL and to highlight current and future trends which will hopefully reshape the overall management of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
- Author
-
Vassilakopoulos, Theodoros P., Panitsas, Fotios, Mellios, Zois, Apostolidis, John, Piperidou, Alexia, Michael, Michalis D, Gurion, Ronit, Akay, Meltem, Hatzimichael, Eleftheria, Karakatsanis, Stamatis J., Dimou, Maria, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Giatra, Chara, Kanellias, Nikolaos, Sayyed, Ayman, Tadmor, Tamar, Kaynar, Leylagul, Zektser, Miri, Symeonidis, Argiris, Atalar, SC, Verrou, Evgenia, Gutwein, Odit, Ganzel, Chezi, Karianakis, Giorgos, Isenberg, Jonathan, Gainaru, Gabriela, Triantafyllou, Theodora, Vrakidou, Efimia, Palassopoulou, Maria, Ozgur, Mehmet, Paydas, Semra, Tsirigotis, Panagiotis, Tsirogianni, Maria, Tuglular, Tulin, Chatzidimitriou, Chrysovalantou, Kotsopoulou, Maria, Terpos, Evangelos, Zikos, Panagiotis, Koumarianou, Argyro, Poziopoulos, Christos, Boutsis, Dimitrios, Gafter-Gvili, Anat, Karmiris, Themistoklis, Angelopoulou, Maria K., Bakiri Papaioannou, Maria, Pangalis, Gerassimos, Panayiotidis, Panayiotis, Ferhanoglu, Burhan, Horowitz, Netanel A., and Papageorgiou, Sotirios
- Published
- 2022
- Full Text
- View/download PDF
9. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era.
- Author
-
Vassilakopoulos, Theodoros P., Panitsas, Fotios, Mellios, Zois, Apostolidis, John, Michael, Michalis, Gurion, Ronit, Ferhanoglu, Burhan, Hatzimichael, Eleftheria, Karakatsanis, Stamatios, Dimou, Maria, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Giatra, Hara, Kanellias, Nick, Sayyed, Ayman, Tadmor, Tamar, Akay, Olga Meltem, and Angelopoulou, Maria K.
- Subjects
CENTRAL nervous system ,DISEASE relapse ,RITUXIMAB ,INDUCTION chemotherapy ,LYMPHOMAS - Abstract
Central nervous system (CNS) involvement is rare in primary mediastinal large B‐cell lymphoma (PMLBCL). We aimed to evaluate the incidence of CNS relapse as first treatment failure event and the effect of the induction chemotherapy regimen, central nervous system ‐ international prognostic index (CNS‐IPI) and other clinical and laboratory variables on the risk of CNS relapse in 564 PMLBCL patients treated with immunochemotherapy. Only 17 patients (3.0%) received CNS prophylaxis. During a 55‐month median follow‐up only 8 patients experienced CNS relapse as first event, always isolated. The 2‐year cumulative incidence of CNS relapse (CI‐CNSR) was 1.47% and remained unchanged thereafter. The CI‐CNSR was not affected by the chemotherapy regimen (R‐CHOP or R‐da‐EPOCH). None of the established International Prognostic Index factors for aggressive lymphomas predicted CNS relapse in PMLBCL. The 2‐year CI‐CNSR in patients with versus without kidney involvement was 13.3% versus 0.96% (p < 0.001); 14.3% versus 1.13% with versus without adrenal involvement (p < 0.001); and 10.2% versus 0.97% with versus without either kidney or adrenal involvement. CNS‐IPI was also predictive (2‐year CI‐CNSR in high‐risk vs. intermediate/low‐risk: 10.37% vs. 0.84%, p < 0.001). However, this association may be driven mainly by kidney and/or adrenal involvement. In conclusion, in PMLBCL, CNS relapse is rare and appears to be strongly associated with kidney and/or adrenal involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis
- Author
-
Karakatsanis, Stamatis, Papageorgiou, Sotirios G., Michail, Michail, Angelopoulou, Maria K., Kalpadakis, Christina, Leonidopoulou, Theoni, Katodritou, Eirini, Kotsopoulou, Maria, Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Lakiotaki, Eleftheria, Boutsis, Dimitrios, Karianakis, George, Symeonidis, Argiris, Gavriatopoulou, Maria, Panayiotidis, Panayiotis, Konstantopoulos, Kostas, Karmiris, Themis, Pangalis, Gerassimos A., and Vassilakopoulos, Theodoros P.
- Published
- 2021
- Full Text
- View/download PDF
11. Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers.
- Author
-
Piperidou, Alexia, Zografos, Eleftherios, Vassilakopoulos, Theodoros J., Angelopoulou, Maria K., Hillas, Georgios, Pappis, Vassiliki, Boutsikas, George, Dimou, Maria, Petevi, Kyriaki, Kanellopoulos, Alexandros, Kyrtsonis, Marie-Christine, Panayiotidis, Panayiotis, and Vassilakopoulos, Theodoros P.
- Subjects
HODGKIN'S disease ,CALCITONIN ,BLOOD sedimentation ,C-reactive protein ,BIOMARKERS - Abstract
Background and Objectives: Procalcitonin (PCT) is a useful biomarker for the diagnosis of sepsis. Inflammatory markers are elevated in patients with Hodgkin lymphoma (HL), and yet ongoing infection rarely coexists at diagnosis. PCT levels might be helpful in differentiating bacterial from disease-related inflammation. Materials and Methods: We evaluated serum PCT levels and other inflammation markers in newly diagnosed HL patients. Values < 0.50 ng/mL were considered normal (0.10–0.50 ng/mL: detectable, <0.10 ng/mL: undetectable), while values ≥ 0.50 ng/L were considered elevated. Results: Among 137 patients, 55 had B symptoms (40%), 77/130 (59%) had elevated Erythrocyte Sedimentation Rate (ESR) and 116 (85%) had elevated C-Reactive Protein (CRP) (median 38.1 mg/L (range; 2.97–328)). PCT levels were normal in most patients (undetectable 94/137 (68.5%) and detectable 41/137(30%)) with median value < 0.10 ng/mL (range; <0.10–15.90). Elevated PCT was recorded in only two patients (1.5%). Patients with PCT < 0.10 ng/mL had significantly lower median CRP (25.75; range (2.97–203.0)) compared to patients with PCT ≥ 0.1 ng/mL (median CRP 92.50 mg/L; range (3.34–328.0)). Almost all patients (40/41, 97.6%) with detectable PCT had elevated CRP. Conclusions: This is the first study showing that the inflammation characterizing HL is not associated with PCT elevations, although CRP levels are elevated in 85% of the patients. Normal PCT levels may rule out the possibility of occult infection, thus preventing extensive evaluation, which may delay treatment initiation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
- Author
-
KARAKATSANIS, STAMATIS J., BOUZANI, MARIA, SYMEONIDIS, ARGYRIS, ANGELOPOULOU, MARIA K., PAPAGEORGIOU, SOTIRIOS G., MICHAIL, MICHAIL, GAINARU, GABRIELLA, KOURTI, GEORGIA, SACHANAS, SOTIRIOS, KALPADAKIS, CHRISTINA, KATODRITOU, EIRINI, LEONIDOPOULOU, THEONI, KOTSIANIDIS, IOANNIS, HATZIMICHAEL, ELEFTHERIA, KOTSOPOULOU, MARIA, DIMOU, MARIA, VARIAMIS, ELENI, BOUTSIS, DIMITRIOS, KANELLIAS, NICK, and DIMOPOULOU, MARIA N.
- Subjects
RITUXIMAB ,CANCER radiotherapy ,MONOCLONAL antibodies ,CYCLOPHOSPHAMIDE ,DISEASE progression - Abstract
Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both RCHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. The Prognostic Significance of Serum Beta-2 Microglobulin (sβ2m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs
- Author
-
Vassilakopoulos, Theodoros P., Arapaki, Maria Panagiota, Diamantopoulos, Panagiotis T, Angelopoulou, Maria K., Nadali, Gianpaolo, Tsourouflis, Gerasimos, Moschogiannis, Maria, Dimopoulou, Maria, Siakantaris, Marina, Yiakoumis, Xanthi, Kontopidou, Flora, Kalpadakis, Christina H., Gainaru, Gabriela, Asimakopoulos, John V., Dimou, Maria, Sachanas, Sotirios, Kyrtsonis, Marie-Christine, Tsaftaridis, Panayiotis, Plata, Eleni, Variami, Eleni, Viniou, Nora-Athina, Pizzolo, Giovanni, Sarris, Andreas H., Konstantopoulos, Kostas, Panayiotidis, Panayiotis, and Pangalis, Gerassimos
- Published
- 2022
- Full Text
- View/download PDF
14. Identification of Very Low‐Risk Subgroups of Patients with Primary Mediastinal Large B‐Cell Lymphoma Treated with R‐CHOP.
- Author
-
Vassilakopoulos, Theodoros P., Michail, Michail, Papageorgiou, Sotirios, Kourti, Georgia, Angelopoulou, Maria K., Panitsas, Fotios, Sachanas, Sotirios, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Kotsopoulou, Maria, Dimou, Maria, Variamis, Eleni, Boutsis, Dimitrios, Terpos, Evangelos, Dimopoulou, Maria N., Karakatsanis, Stamatios, and Michalis, Eurydiki
- Subjects
DISEASE progression ,CANCER chemotherapy ,MULTIVARIATE analysis ,B cell lymphoma ,MEDIASTINAL tumors ,CANCER patients ,LACTATE dehydrogenase - Abstract
Background: R‐CHOP can cure approximately 75% of patients with primary mediastinal large B‐cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R‐da‐ EPOCH is potentially more effective but also more toxic than R‐CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods: We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients ≤65 years treated with R‐CHOP ± radiotherapy in a multicenter setting in Greece and Cyprus. Results: With a median follow‐up of 69 months, 5‐year freedom from progression (FFP) was 78% and 5‐year lymphoma specific survival (LSS) was 89%. On multivariate analysis, extranodal involvement (E/IV) and lactate dehydrogenase (LDH) ≥2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age‐adjusted IPI by Harrel's C rank parameter and Akaike information criterion. Both models A and B defined high‐risk subgroups (13%–27% of patients [pts]) with approximately 19%–23% lymphoma‐related mortality. They also defined subgroups composing approximately one‐fourth or one‐half of the patients, with 11% risk of failure and only 1% or 4% 5‐year lymphoma‐related mortality. Conclusion: The combination of E/IV with either bulky disease or LDH ≥2 times upper limit of normal defined high‐risk but not very‐high‐risk subgroups. More importantly, their absence defined subgroups comprising approximately one‐fourth or one‐half of the pts, with 11% risk of failure and minimal lymphoma‐related mortality, who may not need more intensive treatment such as R‐da‐EPOCH. Implications for Practice: By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B‐cell lymphoma homogeneously treated with R‐CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R‐CHOP and do not need more intensive regimens such as R‐da‐EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age‐adjusted IPI). This article presents data on a large number of patients with primary mediastinal (thymic) large B‐cell lymphoma and reports a powerful prognostic factor analysis to identify high‐ or low‐risk risk subgroups for risk‐adapted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report.
- Author
-
Diavati, Stavrianna, Asimakopoulos, John V., Galopoulos, Dimitrios, Konstantinou, Iliana, Argyrakos, Theodore, Toulas, Panagiotis, Vassilakopoulos, Theodoros P., Konstantopoulos, Kostas, and Angelopoulou, Maria K.
- Published
- 2021
- Full Text
- View/download PDF
16. Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
- Author
-
Terpos, Evangelos, Gavriatopoulou, Maria, Fotiou, Despina, Giatra, Chara, Asimakopoulos, John V., Dimou, Maria, Sklirou, Aimilia D., Ntanasis-Stathopoulos, Ioannis, Darmani, Ismini, Briasoulis, Alexandros, Kastritis, Efstathios, Angelopoulou, Maria K., Baltadakis, Ioannis, Panayiotidis, Panayiotis, Trougakos, Ioannis P., Vassilakopoulos, Theodoros P., Pagoni, Maria, and Dimopoulos, Meletios A.
- Published
- 2021
- Full Text
- View/download PDF
17. P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome.
- Author
-
Vassilakopoulos, Theodoros P., Liaskas, Athanasios, Rizzuto, Giuliana, Symeonidis, Argyrios, Palma, Marzia, Angelopoulou, Maria K., Giatra, Chara, Kondopidou, Flora, Dimou, Maria, Musseti, Alberto, Xagoraris, Ioanna, Siakantaris, Marina, Verigou, Evgenia, Panitsas, Fotios, Asimakopoulos, John, Arapaki, Maria, Chatzidimitriou, Chrysovalantou, Belia, Marina, Sachanas, Sotirios, and Korkolopoulou, Penelope
- Published
- 2022
- Full Text
- View/download PDF
18. P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers.
- Author
-
Piperidou, Alexia, Zografos, Eleftherios, Vassilakopoulos, Theodoros P., Angelopoulou, Maria K., Hlias, Georgios, Pappis, Vassiliki, Boutsikas, George, Dimou, Maria, Petevi, Kyriaki, Kanellopoulos, Alexandros, Kyrtsonis, Marie‐Christine, and Panayiotidis, Panayiotis
- Published
- 2022
- Full Text
- View/download PDF
19. Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.
- Author
-
Chatzidimitriou, Chrysovalantou, Rondogianni, Phivi, Arapaki, Maria, Liaskas, Athanasios, Plata, Eleni, Angelopoulou, Maria K., Tsirigotis, Panagiotis, and Vassilakopoulos, Theodoros P.
- Subjects
ACUTE myeloid leukemia ,RADIOTHERAPY ,MONOCYTOSIS ,PANCYTOPENIA ,LYMPHOMAS - Abstract
Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits the omission of consolidative radiotherapy in the majority of patients. Patient: We describe a 27-year-old female patient, who achieved a complete remission after treatment with six cycles of R-DA-EPOCH (up to the final level). At 6 months after the end of treatment, PET/CT revealed an unexpected, diffusely increased
18 FDG uptake by the bone marrow. Simultaneously, pancytopenia with monocytosis was observed. Result: The patient was diagnosed with therapy-related myelodysplastic syndrome, which rapidly evolved into acute myeloid leukemia (t-MDS/AML) with MLL rearrangements. She achieved a complete remission after induction therapy, received an allogenic transplant and remains disease-free 2 years later. Conclusions: The extremely early onset of t-MDS/AML, together with the unexpected PET/CT findings make this case unique and highlights the need for the accurate estimation of the possible dose-dependent risk of t-MDS/AML after R-DA-EPOCH in the real-life setting in patients with PMLBCL. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature.
- Author
-
Asimakopoulos JV, Lalou E, Seferlis G, Malliarou M, Konstantinou E, Drandakis I, Vasilopoulos I, Georgopoulou AN, Kopsaftopoulou A, Machairas A, Piperidou A, Karapaschalidis A, Lefaki ME, Galopoulos D, Arapaki MP, Petsa P, Benekou E, Siakantaris MP, Papavassiliou AG, Tsaftaridis P, Panayiotidis P, Vassilakopoulos TP, Papapanagiotou A, and Angelopoulou MK
- Abstract
Data on antibody response (AR) after vaccination against SARS-CoV2 in hematopoietic stem-cell transplantation setting (HSCT) were initially scarce, mainly due to the exclusion of such patients from approval studies. Shortly after the worldwide application of vaccination against SARS-CoV-2 in vulnerable populations such as patients with hematologic malignancies, limited single-center trials, including HSCT patients, were published. However, there was a great heterogeneity between them regarding the type of underlying malignancy, co-current treatment, type of vaccine, method of AR measurement, and time point of AR measurement. Herein, we present the results of a prospective study on AR after vaccination for SARS-CoV-2 using the BNT162b2 vaccine in a cohort of 54 HSCT recipients-mostly autologous from a single Unit-along with a broad review of the current literature. In our cohort, the AR positivity rate at 1 month was 80.8% and remained positive in 85.7% of patients at 3 months after vaccination. There were only nine non-responders, who were more heavily pretreated and more frequently hypogammaglobulinemic compared to responders. High antibody titers (AT), [AT ≥ 1000 U/mL], were detected in 38.5% and 30.6% of the patients at m
1 and m3 , respectively. A significant decline in AT between m1 and m3 was demonstrated- p < 0.0001; median AT1 and AT3 were 480.5 and 293 U/mL, respectively. A novel finding of our study was the negative impact of IgA hypogammaglobulinemia on response to vaccination. Other negative significant factors were treatment with anti-CD20 antibody at vaccination and vaccination within 18 months from HSCT. Our data indicate that HSCT recipients elicit a positive response to the BNT162b2 vaccine against SARS-CoV-2 when vaccinated at 6 months post-transplant, and vaccination should be offered to this patient population even within the post-pandemic COVID-19 era.- Published
- 2024
- Full Text
- View/download PDF
21. Prognostic Impact of Serum β 2 -Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients.
- Author
-
Vassilakopoulos TP, Arapaki M, Diamantopoulos PT, Liaskas A, Panitsas F, Siakantaris MP, Dimou M, Kokoris SI, Sachanas S, Belia M, Chatzidimitriou C, Konstantinou EA, Asimakopoulos JV, Petevi K, Boutsikas G, Kanellopoulos A, Piperidou A, Lefaki ME, Georgopoulou A, Kopsaftopoulou A, Zerzi K, Drandakis I, Dimopoulou MN, Kyrtsonis MC, Tsaftaridis P, Plata E, Variamis E, Tsourouflis G, Kontopidou FN, Konstantopoulos K, Pangalis GA, Panayiotidis P, and Angelopoulou MK
- Abstract
The significance of serum beta-2 microglobulin (sβ
2 m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ2 m levels were measured by a radioimmunoassay (upper normal limit 2.4 mg/L). Sequential cutoffs (1.8-3.0 by 0.1 mg/L increments, 3.5 and 4.0 mg/L) were tested along with ROC analysis. The median sβ2 m levels were 2.20 mg/L and were elevated (>2.4 mg/L) in 383/915 patients (41.9%). Higher sβ2 m was associated with inferior freedom from progression (FFP) at all tested cutoffs. The best cutoff was 2.0 mg/L (10-year FFP 83% vs. 70%, p = 0.001), which performed better than the 2.4 mg/L cutoff ("normal versus high"). In multivariate analysis, sβ2 m > 2.0 mg/L was an independent adverse prognostic factor in the whole patient population. In multivariate overall survival analysis, sβ2 m levels were predictive at 2.0 mg/L cutoff in the whole patient population and in advanced stages. Similarly, sβ2 m > 2.0 mg/L independently predicted inferior HL-specific survival in the whole patient population. Our data suggest that higher sβ2 m is an independent predictor of outcome in HL but the optimal cutoff lies within the normal limits (i.e., at 2.0 mg/L) in this predominantly young patient population, performing much better than a "normal versus high" cutoff set at 2.4 mg/L.- Published
- 2024
- Full Text
- View/download PDF
22. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
- Author
-
Vassilakopoulos TP, Piperidou A, Mellios Z, Verigou E, Katodritou E, Kalpadakis C, Papageorgiou SG, Chatzidimitriou C, Prassopoulos V, Siakantaris MP, Giatra H, Karantanis D, Papathanasiou N, Ligdi L, Kopsaftopoulou A, Leonidopoulou T, Xanthopoulos V, Karakatsanis S, Vrakidou E, Chatziioannou S, Drougkas D, Hatzimichael E, Gainaru G, Palassopoulou M, Tsirogianni M, Kotsopoulou M, Tsourouflis G, Skoura E, Mainta C, Terpos E, Poziopoulos C, Triantafyllou T, Zikos P, Koumarianou A, Liapi D, Pappa V, Verrou E, Tsirigotis P, Labropoulou V, Papadaki H, Datseris I, Symeonidis A, Bouzani M, Bakiri M, Karmiris T, Angelopoulou MK, and Rondogianni P
- Abstract
Competing Interests: ET is a HemaSphere Editor. The authors have no conflicts of interest to disclose.
- Published
- 2023
- Full Text
- View/download PDF
23. Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance.
- Author
-
Karakatsanis S, Panitsas F, Arapaki M, Galopoulos D, Asimakopoulos JV, Liaskas A, Chatzidimitriou C, Belia M, Konstantinou E, Vassilopoulos I, Papadatos SS, Sachanas S, Efstathopoulou M, Yiakoumis X, Pardalis V, Iliakis T, Giannakopoulou N, Dimou M, Chatzidavid S, Boutsikas G, Petevi K, Kanellopoulos A, Gainaru G, Variamis E, Siakantaris MP, Kyrtsonis MC, Plata E, Tsaftaridis P, Dimopoulou MN, Viniou NA, Syrigos KN, Pangalis GA, Panayiotidis P, Konstantopoulos K, Angelopoulou MK, and Vassilakopoulos TP
- Subjects
- Biomarkers, Ferritins, Humans, Male, Prognosis, Progression-Free Survival, Retrospective Studies, Hodgkin Disease diagnosis, Hodgkin Disease therapy
- Abstract
Serum ferritin (SF) is frequently elevated in classical Hodgkin lymphoma (cHL). We report on its prognostic significance in an unselected series of 529 cHL patients treated with state-of-the-art therapy. Higher baseline levels correlated with markers of advanced/aggressive disease. SF levels were significantly higher in male and older patients, those with high body mass index and mixed cellularity histology. The strongest correlation was recorded between SF and complement reactive protein (CRP) levels. Gender-specific SF cutoffs which provided the best discrimination in terms of freedom from progression (FFP) were identified. In multivariate analysis elevated SF levels, advanced stage and high lactate dehydrogenase (LDH) were independent prognostic factors of inferior FFP. SF also appears to retain independent prognostic significance for progression-free survival (PFS) but not for overall survival (OS). In conclusion, SF levels in cHL reflect disease activity and are associated with adverse patient outcomes.
- Published
- 2022
- Full Text
- View/download PDF
24. Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.
- Author
-
Chatzidimitriou C, Rondogianni P, Arapaki M, Liaskas A, Plata E, Angelopoulou MK, Tsirigotis P, and Vassilakopoulos TP
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide, Doxorubicin, Etoposide, Female, Humans, Positron Emission Tomography Computed Tomography, Prednisone, Vincristine, Leukemia, Myeloid, Acute chemically induced, Leukemia, Myeloid, Acute genetics, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits the omission of consolidative radiotherapy in the majority of patients., Patient: We describe a 27-year-old female patient, who achieved a complete remission after treatment with six cycles of R-DA-EPOCH (up to the final level). At 6 months after the end of treatment, PET/CT revealed an unexpected, diffusely increased
18 FDG uptake by the bone marrow. Simultaneously, pancytopenia with monocytosis was observed., Result: The patient was diagnosed with therapy-related myelodysplastic syndrome, which rapidly evolved into acute myeloid leukemia (t-MDS/AML) with MLL rearrangements. She achieved a complete remission after induction therapy, received an allogenic transplant and remains disease-free 2 years later., Conclusions: The extremely early onset of t-MDS/AML, together with the unexpected PET/CT findings make this case unique and highlights the need for the accurate estimation of the possible dose-dependent risk of t-MDS/AML after R-DA-EPOCH in the real-life setting in patients with PMLBCL.- Published
- 2021
- Full Text
- View/download PDF
25. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
- Author
-
Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, Banti A, Arapaki M, Iliakis T, Bouzani M, Verrou E, Spanoudakis E, Giannouli S, Marinakis T, Mandala E, Mparmparousi D, Sachanas S, Dalekou-Tsolakou M, Hatzimichael E, Vadikolia C, Violaki V, Poziopoulos C, Tsirkinidis P, Chatzileontiadou S, Vervessou E, Ximeri M, Sioni A, Konstantinidou P, Kyrtsonis MC, Siakantaris MP, Angelopoulou MK, Pappa V, Konstantopoulos K, Panayiotidis P, and Vassilakopoulos TP
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride adverse effects, Disease-Free Survival, Female, Greece epidemiology, Humans, Immunoconjugates administration & dosage, Immunoconjugates adverse effects, Male, Middle Aged, Rituximab administration & dosage, Rituximab adverse effects, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell mortality
- Abstract
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression-free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 months respectively, while 55% of patients experienced a grade ≥3 adverse event, mainly hematologic. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments., (© 2021 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.